BR112013009709A2 - cisteína e absorção de alimento - Google Patents

cisteína e absorção de alimento

Info

Publication number
BR112013009709A2
BR112013009709A2 BR112013009709A BR112013009709A BR112013009709A2 BR 112013009709 A2 BR112013009709 A2 BR 112013009709A2 BR 112013009709 A BR112013009709 A BR 112013009709A BR 112013009709 A BR112013009709 A BR 112013009709A BR 112013009709 A2 BR112013009709 A2 BR 112013009709A2
Authority
BR
Brazil
Prior art keywords
cysteine
food absorption
malnutrition
prevention
treatment
Prior art date
Application number
BR112013009709A
Other languages
English (en)
Portuguese (pt)
Inventor
Denis Breuille
Isabelle Papet
Karine Vidal
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43304791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013009709(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112013009709A2 publication Critical patent/BR112013009709A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Feed For Specific Animals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
BR112013009709A 2010-10-21 2011-10-19 cisteína e absorção de alimento BR112013009709A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10188399A EP2444083A1 (en) 2010-10-21 2010-10-21 Cysteine and food intake
PCT/EP2011/068231 WO2012052463A1 (en) 2010-10-21 2011-10-19 Cysteine and food intake

Publications (1)

Publication Number Publication Date
BR112013009709A2 true BR112013009709A2 (pt) 2016-07-19

Family

ID=43304791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009709A BR112013009709A2 (pt) 2010-10-21 2011-10-19 cisteína e absorção de alimento

Country Status (15)

Country Link
US (1) US9233090B2 (https=)
EP (2) EP2444083A1 (https=)
JP (1) JP6160832B2 (https=)
CN (1) CN103269697A (https=)
AU (1) AU2011317627B2 (https=)
BR (1) BR112013009709A2 (https=)
CA (1) CA2815109C (https=)
DK (1) DK2629769T3 (https=)
ES (1) ES2654344T3 (https=)
MX (1) MX2013004371A (https=)
PH (1) PH12013500761A1 (https=)
RU (1) RU2013123062A (https=)
SG (1) SG189935A1 (https=)
WO (1) WO2012052463A1 (https=)
ZA (1) ZA201303656B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
IL296055A (en) 2017-08-14 2022-10-01 Axcella Health Inc Amino acid compositions for the treatment of liver disease
CN111315239A (zh) * 2017-11-21 2020-06-19 雀巢产品有限公司 针对肌肉质量和/或肌肉量使用橄榄苦苷或姜黄素的组合物和方法
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
WO2020163188A1 (en) * 2019-02-08 2020-08-13 Imbria Pharmaceuticals, Inc. Compositions containing n-acetylcysteine conjugated to a tca cycle intermediate
JP7655224B2 (ja) * 2019-10-25 2025-04-02 味の素株式会社 筋質向上剤
CN120282718A (zh) 2022-09-30 2025-07-08 赢创运营有限公司 用于治疗营养不良的益生菌组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
JPS62286923A (ja) * 1986-06-04 1987-12-12 Takao Shinoda 貧食作用増強剤
JPH05294833A (ja) * 1991-04-15 1993-11-09 Takeda Chem Ind Ltd ビタミン含有保健剤
WO1993002682A1 (en) 1991-08-06 1993-02-18 Labco Pharmaceuticals, Inc. Method and compositions for reducing craving for alcohol and stimulants
DE4229166A1 (de) * 1992-09-01 1994-03-03 Deutsches Krebsforsch Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse
FR2711529B1 (fr) 1993-10-28 1996-07-05 Clintec Nutrition Cy Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
US5627152A (en) * 1995-01-18 1997-05-06 Telluride Pharmaceutical Corporation Method for increasing bodyweight
US5770217A (en) 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement
RO119122B1 (ro) * 1998-02-02 2004-04-30 Dumitru Dobrescu Medicament geriatric
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
PL363426A1 (en) * 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20090209647A1 (en) 2005-06-14 2009-08-20 Nestec S.A. Nutritional method
DE102005062417A1 (de) * 2005-12-27 2007-08-23 Korth, Ruth-Maria, Dr.med. Kompositionen mit spezifischen und unspezifischen Lipidantagonisten
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
JP2009001507A (ja) 2007-06-19 2009-01-08 Ss Pharmaceut Co Ltd 体脂肪減少剤およびその利用
WO2009157759A1 (en) 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
TWI515005B (zh) 2008-09-12 2016-01-01 ２４５８７８１加拿大公司 在接受化療或放療的患者中應用富含半胱胺酸之乳清衍生蛋白以增進患者存活時間
CA2740911C (en) 2008-10-17 2014-07-29 Nestec S.A. Whey protein compositions, methods and uses

Also Published As

Publication number Publication date
AU2011317627B2 (en) 2016-06-02
EP2444083A1 (en) 2012-04-25
JP2014504261A (ja) 2014-02-20
EP2629769A1 (en) 2013-08-28
WO2012052463A1 (en) 2012-04-26
JP6160832B2 (ja) 2017-07-12
CA2815109A1 (en) 2012-04-26
MX2013004371A (es) 2013-08-27
CN103269697A (zh) 2013-08-28
CA2815109C (en) 2020-03-24
DK2629769T3 (en) 2018-01-02
SG189935A1 (en) 2013-06-28
AU2011317627A1 (en) 2013-05-23
PH12013500761A1 (en) 2017-08-23
EP2629769B1 (en) 2017-10-04
RU2013123062A (ru) 2014-11-27
US9233090B2 (en) 2016-01-12
ZA201303656B (en) 2014-11-26
ES2654344T3 (es) 2018-02-13
US20130225486A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
BR112013009709A2 (pt) cisteína e absorção de alimento
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CL2014000801A1 (es) Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
BR112016003723A2 (pt) sanitização de alimento
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
MX2015010139A (es) Composicion antiseptica oral para tratamiento de mucositis oral.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX342947B (es) Tratamiento de diabetes tipo 2.
EP3310366A4 (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BRPI0610786B8 (pt) uso de um ou mais oligossacarídeos ácidos e neutros, e cisteína e/ou fonte de cisteína, e, composição alimentícia
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
MX2019007555A (es) Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.
TR201908639T4 (tr) Dejeneratif göz bozukluklarının önlenmesi ve veya tedavisine yönelik safran bazlı bileşimler.
EA201491426A1 (ru) Новые фармацевтические композиции, содержащие фосфатидилсерин и куркумин
PT3016666T (pt) Formulação de óleo marinho que compreende resveratrol ou derivados do mesmo para utilizar no tratamento, retardamento e/ou prevenção de doença de alzheimer
BR112015025760A2 (pt) produto de massa ou massa crua compreendendo grãos funcionalizados
BR112014000795A2 (pt) uso cosmético e/ou dermatológico de compostos oligossacarídeos na prevenção e no tratamento de estrias
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]